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S U M M A R Y
Background: Insulin resistance is highly prevalent in patients with chronic hepatitis C (CHC) and to some
extent accounts for ﬁbrosis and reducing viral eradication. Activated cannabinoid 1 receptor (CB1R)
signaling has been implicated in the development of phenotypes associated with insulin resistance and
steatosis. We investigated the role of the endocannabinoid system in glucose metabolism disorders
induced by hepatitis C virus (HCV) replication.
Methods: Human hepatic stellate cells (HSC; LX-2 cells) were co-cultured with Huh-7.5 cells or Huh-7.5
cells harboring HCV replicon (replicon cells). Endocannabinoid levels were then measured by liquid
chromatography/mass spectrometry. The expression of CB1R and its downstream glucose metabolism
genes in hepatocytes were determined by real-time PCR and Western blot. Glucose uptake by
hepatocytes and glucose production were measured. Glucose metabolism tests and measurements of
HCV RNA levels and nonstructural protein 5A (NS5A) levels were taken after treatment with CB1R
agonist arachidonyl-2-chloroethanolamide (ACEA) or antagonist AM251.
Results: Compared to the co-culture with Huh-7.5 cells, the level of 2-arachidonoylglycerol (2-AG) and
the CB1R mRNA and protein levels increased in the co-culture of LX-2 cells with replicon cells. The
activation of CB1R decreased AMP-activated protein kinase (AMPK) phosphorylation, inhibited cell
surface expression of glucose transporter 2 (GLUT2), and suppressed cellular glucose uptake;
furthermore, it increased cyclic AMP response element-binding protein H (CREBH), then up-regulated
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) genes and down-
regulated the glucokinase (GK) gene, thus promoting glucose production. Interferon treatment restored
the aforementioned changes. CB1R antagonist improved glucose metabolism disorders by an increase in
glucose uptake and a decrease in glucose production, and inhibited HCV replication.
Conclusions: HCV replication may not only increase the 2-AG content, but may also up-regulate the
expression of CB1R of hepatocytes, then change the expression proﬁle of glucose metabolism-related
genes, thereby causing glucose metabolism disorders of hepatocytes and promoting HCV replication.
Treatment with CB1R antagonist improved glucose metabolism disorders and inhibited viral genome
replication.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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The hepatitis C virus (HCV) infects approximately 170 million
people worldwide, and a proportion of these will develop cirrhosis
and hepatocellular carcinoma.1 Metabolic factors, namely insulin* Corresponding author. Tel.: +86 0451 86605614; fax: +86 0451 86605614.
E-mail address: yujianwu45@sina.com.cn (J.-W. Yu).
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1201-9712  2014 The Authors. Published by Elsevier Ltd on behalf of International Soresistance and steatosis, are frequent ﬁndings in patients with
chronic hepatitis C (CHC). Insulin resistance is frequently observed
in non-obese patients, and 36.8% of patients with CHC were shown
to have a homeostasis model assessment-insulin resistance
(HOMA-IR) index 2.5.2 These metabolic features are indepen-
dently associated with the severity of liver damage3 and are
negative predictors of a sustained virological response (SVR) after
standard antiviral therapy.4 We have proved that HCV replication
may cause a disturbance in glucose metabolism via the silentciety for Infectious Diseases. Open access under CC BY-NC-SA license.
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(AMPK) signaling pathway.5,6 However the molecular mechanism
behind this phenomenon has yet to be explored.
The endocannabinoid system (ECS) consists of cannabinoid
receptors, endocannabinoids, and the enzymes involved in their
biosynthesis and degradation, and is present both in the brain
and peripheral tissues, including the liver.7 Endocannabinoids
include anandamide and 2-arachidonoylglycerol (2-AG). There
are two G protein-coupled cannabinoid receptors, CB1 and CB2.8
Endocannabinoids acting through cannabinoid 1 receptor (CB1R)
have a strong anabolic effect and the activation of hepatic CB1R
increases the activity of lipogenic and gluconeogenic transcrip-
tion factors.9 Thus, CB1 activation is associated with insulin
resistance and dyslipidemia. Additionally, up-regulation of the
hepatic CB1R may contribute to chronic liver inﬂammation,
ﬁbrosis, and cirrhosis induced by obesity, alcoholism, and viral
hepatitis.10
Several lines of investigation have suggested the crucial role of
the hepatic cannabinoid system, which appears to be mediated via
activation of cannabinoid receptors, in the pathogenesis of non-
alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohe-
patitis (NASH).11,12 Two recent studies suggested that the
expression of CB1R is up-regulated in liver samples from CHC
patients,13 and that the activation of the cannabinoid system is
crucial for lipid accumulation in HCV replicon cells.14 Antagonism
of peripheral hepatic CB1R improves insulin sensitivity and liver
carbohydrate and lipid metabolism in cultured mouse liver
slices.15 However, it is unclear whether insulin resistance
promotes the development of CHC via activation of the endo-
cannabinoid/cannabinoid receptor signaling pathway. We specu-
lated that the cannabinoid signal pathway may play an important
role in hepatic glucose disorders in HCV infection. In this study we
investigated the role of the endocannabinoid system in insulin
resistance induced by HCV infection using a co-culture system of
Huh-7.5 cells harboring HCV replicon and hepatic stellate cells
(HSC).
2. Materials and methods
2.1. Cell culture
Huh-7.5 cells and Huh-7.5 cells harboring HCV replicon
(hereafter referred to as replicon cells) were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Hyclone, Logan, UT, USA)
containing 10% fetal bovine serum (FBS; Hyclone), 100 units/ml
penicillin (Hyclone), and 100 mg/ml streptomycin (Hyclone) at
37 8C in a humidiﬁed 5% CO2 incubator and passaged every 3 days
by trypsinization. Replicon cells harboring a full-length HCV-1b
RNA replicon derived from pON/C-5B, autonomously replicate to
express all the HCV proteins (the core protein, E1, E2, p7, NS2, NS3
to NS5B).6 Replicon cells were treated with 1000 IU/ml of alpha
interferon (IFN; Sigma Chemical, St. Louis, MO, USA) for 10 days to
eliminate HCV replication.
HSC (LX-2 cells) were purchased from the cell bank of the
Chinese Academy of Science. The Huh-7.5 cells and replicon cells
and replicon cells with IFN treatment were then cultured in serum-
free medium overnight (serum starvation) and co-incubated with
LX-2 cells at a density of 5  107 cells/l. The ratio of hepatocytes to
LX-2 cells was 4:1. LX-2 cells were separated from hepatocytes
using a 0.2-mm Anopore semipermeable membrane (Nalge Nunc.,
Naperville, IL, USA). Following 24 h culture in DMEM supplemen-
ted with 10% FBS, the cells were washed with phosphate buffered
saline (PBS) and cultured for another 24 h in serum-free DMEM.
The medium was then collected to measure endocannabinoid
levels.2.2. Measurement of anandamide and 2-AG
Anandamide and 2-AG levels were determined by liquid
chromatography (LC)/mass spectrometry (MC) as described
previously.16 Lipid extracts of the medium were made by ﬁrst
adding 9.0 ml of a 1:1 mixture of methanol and acetonitrile to
1.0 ml medium. The samples were spiked with 1 nmol of d-8-
anandamide (Deva Biotech, Hatboro, PA, USA) and 10 nmol d-8-2-
AG (Deva Biotech) as internal standards. This solution was
vortexed for 1 min then underwent centrifugation at 19 000  g
at 24 8C for 20 min. The supernatant was fractionated by reverse-
phase high performance LC on an ODS column (Supelcosil, 5 mm,
4.6 mm  15 cm), using a mobile phase of methanol/water/acetic
acid (85:15:0.03 vol/vol/vol) at a ﬂow rate of 1 ml/min. This was
followed by in-line MS analysis on a Micromass Quattro II mass
spectrometer equipped with an atmospheric pressure, chemical
ionization source. Two selected ions were monitored simulta-
neously: selected on monitoring 387.2 for d-8-2-AG ions as the
internal standard, selected on monitoring 379.2 for 2-AG ions,
selected on monitoring 356.2 for d-8-anandamide ions as the
internal standard, and selected on monitoring 348.2 for ananda-
mide ions.
2.3. Glucose uptake by hepatocytes
The Huh-7.5 cells and replicon cells and replicon cells with IFN
treatment were cultured in 12-well plates for the glucose uptake
assay. After serum starvation overnight in 0.1% bovine serum
albumin–DMEM, the cells were subsequently incubated in 1 ml of
PBS containing 100 nM insulin for 30 min at 37 8C. After washing
with PBS, cells were incubated in 1 ml of PBS containing 1 mCi of 2-
deoxy-D-[3H] glucose/ml (ICN, Costa Mesa, CA, USA) for 5 min. The
reaction was stopped by adding 0.1 mM cytochalasin B on ice. The
cells were washed with ice-cold PBS and solubilized in 0.4 ml of
NaOH (0.05 M). The incorporated radioactivity was measured in
4 ml of scintillation ﬂuid by liquid scintillation counter (LS6500;
Beckman Coulter, Fullerton, CA, USA).
2.4. Glucose production assay
The Huh-7.5 cells and replicon cells and replicon cells with IFN
treatment were cultured in 12-well plates for the glucose
production assay. Culture medium was replaced with glucose
production buffer consisting of glucose-free DMEM, without
phenol red, supplemented with a gluconeogenic substrate
(2 mM sodium pyruvate and 20 mM sodium lactate). After 24 h
of incubation, the medium was collected, and the total glucose
concentration was measured using the Glucose Assay Kit II
(Biovision, CA, USA) and normalized to the cellular protein content.
As the baseline of glucose production, glucose-free DMEM with
neither sodium pyruvate nor sodium lactate was used. Glucose
production via gluconeogenesis equals the total glucose produc-
tion minus the baseline glucose production.
2.5. Real-time PCR analysis of mRNA levels of CB1 and glucose
metabolism-related genes
Total cellular RNA was isolated using the TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) in accordance with the manufac-
turer’s protocol. cDNA was generated using the Quanti Tect
Reverse Transcription system (Qiagen, Valencia, CA, USA). Real-
time quantitative PCR was performed on a SYBR Premix Ex Taq
(Takara Bio, Kyoto, Japan) using SYBR green chemistry in an ABI
PRISM 7000 (Applied Biosystems, Foster City, CA, USA). Glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) was used as inter-
nal control for normalization. Table 1 lists the PCR primers for the
Table 1
Sequences of primers used for the real-time PCR
Genes Forward 50–30 Reverse 50–30 PCR products (bp)
CB1R CAGAAGAGCATCATCCACACGTCTG ATGCTGTTATCCAGAGGCTGCGCAGTGC 338
DAGLa CCTCTTCAACCTGGACAGCAA GGGCCCTCAGCGTAGTCA 245
DAGLb TTCCAAGGAGTTCGTGACTGC TTGAAGGCCTTGTTGTCGCC 207
MGL ATGCAGAAAGACTACCCTGGGC TTATTCCGAGAGAGCACGC 135
GLUT1 TGAACCTGCTGGCCTTC GCAGCTTCTTTAGCACA 399
GLUT2 TGG GCTGAGGAAGAGACTGT AGAGACTGAAGGATGGCTCG 461
GK GCCTCCCAAAGCATCTACCTC GCTCCACTGCCCCTCCTCACC 444
G6Pase CCTGGGGCTGGCTCTCAACTC AATAGTAGTCCTCCTCAATCC 309
PEPCK CCAGGCAGTGAGGGAGTTTCT ACTGTGTCTCTTTGCTCTTGG 217
GAPDH GACAACTTTGGCATCGT ATGCAGGGATGATGTTCTGG 133
CB1R, cannabinoid 1 receptor; DAGL, diacylglycerol lipase; MGL, monoglyceride lipase; GLUT, glucose transporter; GK, glucokinase; G6Pase, glucose 6-phosphatase; PEPCK,
phosphoenolpyruvate carboxykinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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lipase alpha (DAGLa) and beta (DAGLb) of LX-2 cells; CB1R,
glucose transporter 1 (GLUT) and 2 (GLUT2), glucokinase (GK),
phosphoenolpyruvate carboxykinase (PEPCK), and glucose-
6-phosphatase (G6Pase) of hepatocytes; and GAPDH. PCR
conditions were as follow: 95 8C for 30 s, 58 8C for 30 s, and
extension at 72 8C for 45 s; 40 cycles. The relative gene
expression analysis was carried out using SDS 3.1 software
(Applied Biosystems).
2.6. Western blot
All the cells in the co-culture system were lysed in buffer
(20 mM Tris–HCl, pH 8.0, 1% Nonidet P-40, 1 mM ethylene diamine
tetraacetic acid (EDTA), 1 mM ethylene glycol tetraacetic acid
(EGTA), 1 mM sodium orthovanadate, 1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl ﬂuoride, 2 mg/ml aprotinin, 2 mg/ml leu-
peptin, and 1 mg/ml pepstatin). Cell debris was removed by
centrifugation at 14 000  g for 15 min at 4 8C, and the cell
supernatant was used for Western blotting. Protein quantiﬁcation
was carried out using a bicinchoninic acid protein assay kit
(Thermo Fisher Scientiﬁc, Rockford, IL, USA). Fifty micrograms of
protein was separated by 10% sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) and electrophoretically
transferred to a polyvinylidene diﬂuoride transfer membrane
(Millipore, Billerica, MA, USA). The membranes were blocked with
5% nonfat dry milk in Tris-buffered saline with 0.1% Tween 20 and
incubated with speciﬁc antibodies (anti-phospho-AMPKa
(Thr172) monoclonal antibody, anti-AMPKa antibody (Cell Signal-
ing Technologies, Beverly, MA, USA), anti-HCV NS5A monoclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
cyclic AMP response element-binding protein H (CREBH) antibody
(Thermo Fisher Scientiﬁc, USA), and anti-CB1 receptor (Afﬁnity
BioReagents, Golden, CO, USA)), followed by incubation with
horseradish peroxidase-conjugated goat anti-mouse IgG or goat
anti-rabbit IgG (Santa Cruz Biotechnology). The respective protein
bands were visualized by the enhanced chemiluminescence
detection system (Perkin Elmer, Waltham, MA, USA). Protein
loading was normalized by probing with b-actin antibody (Santa
Cruz Biotechnology).
2.7. Cell viability
The effect of CB1R agonist arachidonyl-2-chloroethanolamide
(ACEA; Tocris Bioscience, Avonmouth, Bristol, UK) and antagonist
AM251 (Tocris Bioscience) on cell viability was investigated. The
cells were seeded at a density of 2  105 cells per dish onto 6-well
plates. After 24 h culture, the cells were treated with ACEA (1–
10 nM) or AM251 (1–10 nM) in the absence of G418. After
incubation for 72 h, the number of viable cells was counted in animproved Neubauer-type hemocytometer after trypan blue dye
(Invitrogen) treatment.
2.8. HCV RNA level
The HCV RNA level was quantiﬁed by real-time PCR (in an ABI
Prism 7000 Real-Time Thermocycler), with the use of HCV analyte-
speciﬁc reagents (ASRs, Abbott) from the Pathology Clinical
Laboratory at Saint Louis University.
2.9. Statistical analysis
Results were expressed as the mean  standard deviation.
Signiﬁcance was analyzed using the Student’s t-test, and statistical
signiﬁcance was deﬁned as p < 0.05.
3. Results
3.1. Effect of HCV replication on endocannabinoid levels
Compared to those co-cultured with Huh-7.5 cells, cells in the
co-culture of LX-2 cells with replicon cells showed a signiﬁcant
difference. The level of 2-AG (80.5  20.1 vs. 30.0  5.0 pmol/106
cells, t = 5.941, p < 0.01) increased, which was restored by IFN
treatment (32.9  6.2 vs. 30.0  5.0 pmol/106 cells, t = 0.909,
p > 0.05) (Figure 1). The mRNA level of DAGLb (the enzyme
responsible for the synthesis of 2-AG) increased (2.4  0.5 vs.
1.0  0.3, t = 5.881, p < 0.01), and was restored by IFN treatment
(0.9  0.2 vs. 1.0  0.3, t = 0.679, p > 0.05). The mRNA levels of
DAGLa and MGL (the enzymes responsible for the selective
degradation of 2-AG) decreased signiﬁcantly (DAGLa 0.4  0.1 vs.
1.0  0.3, t = 4.648, p < 0.01; MGL 0.5  0.2 vs. 1.0  0.3, t = 3.397,
p < 0.01), and they were restored by IFN treatment (DAGLa 0.9  0.2
vs. 1.0  0.3, t = 0.679, p > 0.05; MGL 0.9  0.2 vs. 1.0  0.3, t = 0.679,
p > 0.05) (Figure 1). No signiﬁcant difference was seen in anandamide
level between co-cultured with Huh-7.5 cells and replicon cells
(0.13  0.03 vs. 0.15  0.05 pmol/106 cells, t = 0.840, p > 0.05).
Anandamide and 2-AG were not detected in the single culture
medium from LX-2 cells or Huh-7.5 cells or replicon cells.
3.2. Effect of HCV replication on CB1R levels
Compared to those co-cultured with Huh-7.5 cells, the
expression level of CB1R protein of hepatocytes (0.8  0.2 vs
0.3  0.1, t = 5.477, p < 0.01) increased in the cells co-cultured with
LX-2 cells with replicon cells, and it was restored by IFN treatment
(0.4  0.1 vs 0.3 0 .1, t=1.577, p > 0.05) (Figure 2). The mRNA level
of CB1R (3.3 0 .7 vs 1.0  0.2, t = 7.739, p < 0.01) increased, and was
restored by IFN treatment (0.9  0.2 vs 1.0  0.2, t=0.866, p > 0.05)
(Figure 3).
Figure 1. Effect of HCV replication on the endocannabinoid system. (a) Level of 2-
AG. (b) Transcriptional levels of the enzymes responsible for the biosynthesis and
degradation of 2-AG. The 2-AG level was measured by liquid chromatography/mass
spectrometry. The transcriptional levels of the enzymes responsible for the
biosynthesis and degradation of 2-AG were examined by real-time quantitative
PCR. Each data point represents the mean  standard deviation of six individual
experiments. (Abbreviations: 2-AG, 2-arachidonoylglycerol; IFN, interferon; DAGL,
diacylglycerol lipase; MGL, monoglyceride lipase.)
Figure 2. Effect of HCV replication on the expression of CB1R, AMPK, phospho-
AMPK, and CREBH protein. (a) The expression of NS5A, CB1R, AMPK, phospho-
AMPK, and CREBH protein by Western blot: lane 1, Huh-7.5 cells; lane 2, replicon
cells; lane 3, replicon cells with IFN treatment. (b) Signal quantiﬁcation by
densitometry of NS5A, CB1R, AMPK, phospho-AMPK, and CREBH protein
normalized to b-actin expression; the data shown are the mean  standard
deviation of six independent experiments. (Abbreviations: CB1R, cannabinoid 1
receptor; AMPK, AMP-activated protein kinase; CREBH, cyclic AMP response element-
binding protein H; NS5A, nonstructural protein 5A; IFN, interferon.)
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HCV nonstructural protein 5A (NS5A) was detected in replicon
cells by Western blot, and not detected in Huh-7.5 cells or replicon
cells with IFN treatment (Figure 2). Compared to Huh-7.5 cells, in
replicon cells, the expression level of phospho-AMPK protein
decreased (0.3  0.1 vs. 0.7  0.2, t = 4.382, p < 0.01), and its level
was restored by IFN treatment (0.6  0.2 vs. 0.7  0.2, t = 0.866,
p > 0.05); the expression level of CREBH protein increased (0.9  0.3
vs. 0.6  0.2, t = 2.038, p < 0.05), and its level was restored by IFN
treatment (0.7  0.2 vs. 0.6  0.2, t = 0.866, p > 0.05). There was no
difference in expression level of AMPK protein between replicon cells
and Huh-7.5 cells (0.8  0.2 vs. 0.7  0.3, t = 0.679, p > 0.05)
(Figure 2).
3.4. Effect of HCV replication on glucose uptake and glucose
production
Compared to Huh-7.5 cells, in replicon cells, the glucose uptake
level of hepatocytes decreased (cpm 4500  500 vs. 20 000  4600,
t = 8.253, p < 0.01), and it was restored by IFN treatment (cpm
19 000  3500 vs. 20 000  4600, t = 0.424, p > 0.05) (Figure 3); the
glucose production level of hepatocytes increased (2.6  0.5 vs.
1.0  0.2, t = 7.278, p < 0.01), and IFN treatment canceled the
enhanced glucose production (1.1  0.3 vs. 1.0  0.2, t = 0.679,
p > 0.05) (Figure 3).
3.5. Effect of HCV replication on mRNA levels of glucose metabolism-
related genes
Compared to Huh-7.5 cells, in replicon cells, the mRNA level of
GLUT2 decreased (0.3  0.1 vs. 1.0  0.2, t = 7.668, p < 0.01), and itwas restored by IFN treatment (0.9  0.3 vs. 1.0  0.2, t = 0.679,
p > 0.05). The mRNA level of GK decreased (0.5  0.1 vs. 1.0  0.2,
t = 5.477, p < 0.01) and the mRNA level of PEPCK (2.6  0.6 vs.
1.0  0.3, t = 5.842, p < 0.01) and G6Pase (2.5  0.5 vs. 1.0  0.2,
t = 6.822, p < 0.01) increased, and the levels were restored by IFN
treatment (GK, 0.9  0.3 vs. 1.0  0.2, t = 0.577, p > 0.05; PEPCK,
1.1  0.3 vs. 1.0  0.3, t = 0.679, p > 0.05; G6Pase, 1.1  0.3 vs.
1.0  0.2, t = 0.679, p < 0.01). There was no signiﬁcant difference in
GLUT1 mRNA level between replicon cells and Huh-7.5 cells
(0.9  0.2 vs. 1.0  0.3, t = 0.679, p > 0.05) (Figure 3).
3.6. Cell viability of replicon cells after addition of ACEA and AM251
Since it has been reported that the proliferation of the HCV
genomic replicon is dependent on host cell growth, we examined
the effect of CB1R agonist ACEA or antagonist AM251 on the cell
number and viability of replicon cells by trypan blue dye exclusion
test. The cytotoxic effect of ACEA or AM251 was not observed in the
cell viability test (Figure 4).
3.7. Effect of CB1 receptor signaling on glucose uptake and glucose
production
In order to study the effect of CB1 receptor signaling on glucose
uptake and glucose production, we treated replicon cells or Huh-
7.5 cells with CB1R agonist ACEA (10 nM) or antagonist AM251
(10 nM) and measured glucose uptake levels and glucose produc-
tion levels. After 48 h of treatment with AM251, glucose uptake
levels increased rapidly and equaled levels of parental Huh-7.5
Figure 3. Effect of HCV replication on glucose metabolism. (a) Effect of HCV
replication on glucose uptake. (b) Effect of HCV replication on glucose production.
(c) Effect of HCV replication on mRNA levels of CB1R and its downstream glucose
metabolism-related genes. The level of glucose uptake was measured by a liquid
scintillation counter. The level of glucose production was measured using a
commercial kit. The transcriptional level of CB1R and its downstream glucose
metabolism-associated genes was examined by real-time quantitative PCR. The
data shown are the mean  standard deviation of six independent experiments.
(Abbreviations: IFN, interferon; cpm, count per min; CB1R, cannabinoid 1 receptor; GK,
glucokinase; PEPCK, phosphoenolpyruvate carboxykinase; G6Pase, glucose 6-
phosphatase; GLUT, glucose transporter.)
Figure 4. Effect of CB1 receptor signaling on glucose metabolism. (a) Cell viability of
replicon cells after the addition of ACEA and AM251. (b) Effect of CB1 receptor
signaling on glucose uptake. (c) Effect of CB1 receptor signaling on glucose
production. The indicated concentrations of ACEA and AM251 were added to the
culture of replicon cells for 72 h. Cell viability was evaluated by trypan blue dye
exclusion assay. Replicon cells and Huh-7.5 cells were treated with CB1R agonist
ACEA (10 nM) or antagonist AM251 (10 nM) for 48 h. The glucose uptake level and
glucose production level were measured. The data shown are the mean  standard
deviation of six independent experiments. (Abbreviations: ACEA, arachidonyl-2-
chloroethanolamide; CB1R, cannabinoid 1 receptor.)
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and equaled levels of parental Huh-7.5 cells (Figure 4), whereas the
agonist had the opposite effect.
3.8. Effect of CB1 receptor signaling on HCV replication
To investigate the effect of CB1 receptor signaling on HCV
genome replication, we analyzed levels of HCV RNA and HCV NS5A
at various time points following treatment of replicon cells with
ACEA and AM251. The levels of HCV RNA and NS5A reduced after
72 h treatment with AM251, whereas they increased after 72 h
treatment with ACEA (Figure 5).
4. Discussion
The present study provides evidence of the involvement of
endocannabinoids acting at hepatic CB1R in the development of
HCV-induced liver glucose metabolism disorders. Several ﬁndings
support this notion. First, HCV replication induced the activation of
the hepatic endocannabinoid system, as reﬂected in the up-
regulation of both CB1 receptor expression and 2-AG levels in the
co-culture system. Second, treatment with CB1R blockade
improved glucose metabolic disorders and inhibited viral genome
replication. Third, the aforementioned metabolic disorders wereselectively suppressed when HCV replication was eliminated by
IFN treatment.
It is well established that the endocannabinoid system
contributes to the control of lipid and glucose metabolism. CB1
receptors have been shown to mediate both alcohol- and diet-
induced hepatic steatosis and insulin resistance by up-regulating
the lipogenic transcription factor sterol regulatory element-
binding protein 1c and increasing de novo fatty acid synthesis
down-regulating transcription factor carnitine palmitoyl transfer-
ase 1 and decreasing fatty acid oxidation.17 Endocannabinoids
contribute to diet-induced insulin resistance in mice via hepatic
CB1-mediated inhibition of insulin signaling and clearance, and
blockade of CB1 receptors enhances insulin sensitivity.18 Further-
more, in well-characterized cohorts with CHC, daily cannabis use is
signiﬁcantly associated with the progression of ﬁbrosis and the
development of severe steatosis and ﬁbrosis.19 However, little
information is available regarding the downstream signaling
pathway involved in this process. In view of the association
between endocannabinoid physiology and glucose metabolism, we
were interested to explore the role that HCV replication plays in
the CB1R signaling pathway and the underlying basis.
Figure 5. Effect of CB1 receptor signaling on HCV replication. (a) Effect of CB1
receptor signaling on HCV NS5A protein. (b) Effect of CB1 receptor signaling on HCV
RNA levels. ACEA or AM251 was added to the medium of replicon cells at a
concentration of 10 nM and incubated for 72 h. Replicon replication was assessed
by immunoblotting for NS5A and HCV RNA levels at various time points.
(Abbreviations: HCV, hepatitis C virus; NS5A, nonstructural protein 5A; RNA,
ribonucleic acid; ACEA, arachidonyl-2-chloroethanolamide.)
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Figure 6. Schematic presentation of the CB1R signaling pathway induced by HCV
replication for glucose metabolism disorders of hepatocytes. HCV replication may
not only increase the 2-AG content secreted by LX-2 cells, but may also up-regulate
the expression of CB1R of hepatocytes, then change the expression proﬁle of glucose
metabolism-related genes, thereby causing metabolism disorders of hepatocytes
and promoting HCV replication. An arrowhead pointing upwards (") represents
activation, an arrowhead pointing downwards (#) represents the repression of
activity. (Abbreviations: CB1R, cannabinoid 1 receptor; HCV, hepatitis C virus; 2-
AG, 2-arachidonoylglycerol; p-AMPK, phospho-AMP-activated protein kinase;
CREBH, cyclic AMP response element-binding protein H; GLUT, glucose
transporter; PEPCK, phosphoenolpyruvate carboxykinase; G6Pase, glucose 6-
phosphatase; GK, glucokinase.)
L.-J. Sun et al. / International Journal of Infectious Diseases 23 (2014) 75–8180The biosynthesis and degradation of anandamide and 2-AG
occur through distinct pathways. Anandamide and 2-AG are
produced ‘on-demand’ from cell membrane precursors in a variety
of cell types, including both neurons and immune-competent cells
in the periphery (B cells, T cells, monocytes/macrophages) and
central nervous system (microglia, astrocytes).20 The induction of
2-AG may be a general response of stellate cells to injury, such as
alcohol and hepatitis virus. The endocannabinoid could not be
detected in single-culture from replicon cells or LX-2 cells. In this
study, we proved that HCV replication may increase 2-AG levels in
LX-2 cells, which is most probably due to the increased expression
of the gene encoding the 2-AG biosynthetic enzyme DAGLb and
the decreased expression of the genes encoding the 2-AG
degradation enzymes MGL and DAGLa. However, previous
research has suggested that the increased 2-AG content of stellate
cells from ethanol-fed mice is related to the increased biosynthesis
of 2-AG but not decreased degradation of 2-AG.21 This difference
requires further exploration.
The liver plays a central role in insulin resistance, reﬂected in
impaired insulin suppression of hepatic glucose production by
down-regulating gluconeogenesis and inhibiting glycogenolysis.
CREBH, an endoplasmic reticulum stress-associated liver-speciﬁc
transcription factor, is emerging to be a key player in regulating
various hepatic metabolic pathways. It directly regulates the
expression of the key hepatic gluconeogenic enzyme genes PEPCK
and G6Pase.22 Previous studies have demonstrated that CREBH is
dramatically induced and activated in diet-induced obese rodent
models.23 In this study, we proved that HCV replication activated
CB1R and increased CREBH, then up-regulated PEPCK and G6Pase
genes and down-regulated glycolytic rate-limiting enzyme GK
gene, thus promoting glucose production. AMPK serves as anintracellular sensor for energy homeostasis. The AMPK pathway
regulates lipid and glucose metabolism. The increase in AMPK
activity reduces glucose production in the liver, whereas it
enhances glucose uptake in the skeletal muscle. In hepatic and
adipose tissues, CB1 agonist treatment has been demonstrated to
inhibit AMPK activity.24 We proved that HCV replication activated
CB1R and decreased AMPK phosphorylation, inhibited cell surface
expression of GLUT2, and suppressed cellular glucose uptake. HCV
infection might induce high concentrations of glucose in hepato-
cytes by CB1R–CREBH and CB1R–AMPK signaling pathways, which
may confer an advantage in efﬁcient replication of HCV.
The changes mentioned above, including the increase in 2-AG,
CB1R expression, and related glucose metabolism genes and
glucose metabolism changes, were canceled when the replication
of HCV was eliminated by IFN. This strongly suggests that the
aforementioned metabolic disorders were selectively suppressed
by HCV replication. To clarify the role of CB1R in the improvement
of glucose metabolism disorders, we treated replicon cells with
special CB1R agonist or antagonist. We proved that the CB1R
antagonist could improve glucose metabolism disturbances by an
increase in glucose uptake and a decrease in glucose production,
and inhibited HCV replication. These ﬁndings suggest that
endocannabinoids and hepatic CB1 receptors are part of a common
pathway involved in the development of glucose metabolism
disorders of hepatocytes by HCV infection.
L.-J. Sun et al. / International Journal of Infectious Diseases 23 (2014) 75–81 81In this study we found the activation of the endocannabinoid
system to be associated with glucose metabolism disorders.
However data on the endocannabinoid system in CHC patients are
lacking, hence we aimed to assess whether circulating and hepatic
endocannabinoids are up-regulated. We found that with the
increase in HOMA-IR, anandamide concentrations in the periph-
eral circulation and the level of CB1R in liver samples obtained
from CHC patients gradually increased (unpublished data). Based
on experimental and therapeutic evidence, hepato-selective CB1R
antagonists with far fewer psychiatric side-effects than ﬁrst-
generation CB1R antagonists may be promising for CHC patients,
especially for those who present insulin resistance and steatosis.
The concomitant administration of these CB1R antagonists with
PEG-IFN plus ribavirin therapy is worth studying.
In conclusion, this study proved that HCV replication may not
only increase 2-AG content, but may also up-regulate the
expression of CB1R of hepatocytes, then change the expression
proﬁle of glucose metabolism-related genes, thereby causing
glucose metabolism disorders of hepatocytes and promoting HCV
replication (Figure 6). Treatment with CB1R blockade improved
glucose metabolic disorders and inhibited viral genome replica-
tion, suggesting that selective targeting of peripheral CB1R may be
effective in anti-HCV therapy for CHC patients with insulin
resistance.
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